TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11475845

Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with active ulcerative colitis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alpha 2‐M activity below 100%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with inflammatory process beyond sigmoid
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 42
Study: 9790438

Group type: EXPERIMENTAL
Intervention: Immunization with SPf66
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no immunization)
Number of subjects: 69
Study: 7608434

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation
Number of subjects: 838
Study: 10149758

Group type: EXPERIMENTAL
Intervention: Contour group (n = 43)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Flat group (n = 45)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 396659

Group type: EXPERIMENTAL
Intervention: Pirenzepine (150 mg daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31158369

Group type: EXPERIMENTAL
Intervention: Prophylactic hemoclips
Number of subjects: 1098

Group type: COMPARATOR
Intervention: No hemoclips
Number of subjects: 1098
Study: 28146459

Group type: COMPARATOR
Intervention: Control group (parent/guardian verbally informed about the anaesthetic procedure)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Informed group (parent/guardian verbally informed and provided with an information leaflet)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Smartphone group (parent/guardian verbally informed and child received a smartphone application)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Smartphone and informed group (parent/guardian received an information leaflet and child received a smartphone application)
Number of subjects: 84
Study: 26452342

Group type: EXPERIMENTAL
Intervention: Oral switch therapy (OST)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Intravenous standard therapy (IST)
Number of subjects: 430
Study: 23842564

Group type: EXPERIMENTAL
Intervention: Reproductive life plan (RLP)-based information provided orally and in writing during contraceptive counselling.
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group 1 (CG1) received standard care without RLP-based information.
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group 2 (CG2) received standard care without RLP-based information.
Number of subjects: 299
Study: 20299956

Group type: EXPERIMENTAL
Intervention: Conjugated pneumococcal vaccine (CPV) + polysaccharide pneumococcal vaccine (PPV)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Polysaccharide pneumococcal vaccine (PPV) alone
Number of subjects: 202
Study: 19271025

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60 mg/day divided into three doses for 6 months
Number of subjects: 32
Study: 16882180

Group type: EXPERIMENTAL
Intervention: Guidelines on the management of psoriasis in primary care and practice‐based nurse‐led training sessions
Number of subjects: 196

Group type: COMPARATOR
Intervention: No guidelines or training sessions
Number of subjects: 196
Study: 12922095

Group type: EXPERIMENTAL
Intervention: 7VPnC plus DTaP‐IPV‐Hib vaccines
Number of subjects: 231

Group type: COMPARATOR
Intervention: DTaP‐IPV‐Hib vaccine plus 7VPnC catch-up vaccination
Number of subjects: 231
Study: 11095261

Group type: EXPERIMENTAL
Intervention: BCL2 antisense oligonucleotides (augmerosen) plus standard dacarbazine treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: BCL2 antisense oligonucleotides (augmerosen)
Number of subjects: 14
Study: 8797612

Group type: EXPERIMENTAL
Intervention: 15 mg/kg BAY x 1351
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: 3 mg/kg BAY x 1351
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 1523304

Group type: EXPERIMENTAL
Intervention: In-111 CYT-103
Number of subjects: 227

Group type: COMPARATOR
Intervention: CT
Number of subjects: 227
Study: 6086371

Group type: EXPERIMENTAL
Intervention: CO2 laser stimulation (50 ms duration, radiant heat pulses between 5 to 20 W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single unit discharges
Number of subjects: 0
Study: 30729631

Group type: EXPERIMENTAL
Intervention: Lecture coupled with a diagnostic workshop (LW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture (L)
Number of subjects: 0
Study: 29648580

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg for 14 days) plus hypofractionated radiotherapy (40 Gy in 15 fractions)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (40 Gy in 15 fractions) without bevacizumab
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus hypofractionated radiotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy without bevacizumab
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cox model of OS controlling for established prognostic factors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cox model of OS including molecular subtypes
Number of subjects: 75
Study: 27189086

Group type: COMPARATOR
Intervention: Daily prednisone (1-2 mg/kg/day for 2-4 weeks with subsequent dose reduction)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pulsed dexamethasone (0.6 mg/kg/day, days 1-4 for six 3-week cycles)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pulsed dexamethasone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Daily prednisone
Number of subjects: 26
Study: 24532031

Group type: EXPERIMENTAL
Intervention: Segment algorithm for perfusion analysis
Number of subjects: 492
Study: 22855333

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4800 IU/d
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 20592647

Group type: COMPARATOR
Intervention: R-methamphetamine (R-MA) 0 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA-d3) 2.5 mg (IV)
Number of subjects: 8
Study: 17296648

Group type: EXPERIMENTAL
Intervention: Esomeprazole, 40 mg bid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17530947

Group type: EXPERIMENTAL
Intervention: Mini-trampoline (MT) training for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dura disc (DT) training for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 15196106

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Intermittent bolus technique (bolus)
Number of subjects: 187
Study: 10690697

Group type: EXPERIMENTAL
Intervention: Use of external hip protectors and encouragement to use the protectors by an adherence nurse
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Use of external hip protectors
Number of subjects: 131
Study: 9354200

Group type: EXPERIMENTAL
Intervention: O 20 mg b.d. + C 500 mg b.d. + A 1 g b.d. for 7 days (OAC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: O 20 mg b.d. + C 250 mg b.d. + M 500 mg b.d. for 7 days (MOC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: C 250 mg b.d. + M 500 mg b.d. for 7 days (CM)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: A 1 g b.d. + clarithromycin (C) 500 mg b.d. for 7 days (AC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: O 20 mg b.d. + amoxycillin (A) 1 g t.d.s. for 14 days (OA)
Number of subjects: 302
Study: 7692146

Group type: EXPERIMENTAL
Intervention: nifedipine GITS
Number of subjects: 394

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 394
Study: 3333018

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium infusions
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 alpha-hydroxyvitamin D3
Number of subjects: 60
Study: 30922759

Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair (EVAR) for intact AAA
Number of subjects: 19336

Group type: EXPERIMENTAL
Intervention: Preoperative predictors of 1-year mortality
Number of subjects: 19336

Group type: EXPERIMENTAL
Intervention: Preoperative statin use
Number of subjects: 19336

Group type: EXPERIMENTAL
Intervention: Prediction model performance
Number of subjects: 19336
Study: 28540452

Group type: EXPERIMENTAL
Intervention: Virtual Reality Driving Simulation Training (VRDST)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine Training (RT)
Number of subjects: 51
Study: 25834594

Group type: EXPERIMENTAL
Intervention: Nano-hydroxyapatite (NHA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium-enriched mixture (CEM)
Number of subjects: 20
Study: 24793366

Group type: EXPERIMENTAL
Intervention: Vaccine (succinylnorcocaine conjugated to cholera toxin B protein)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High IgG group (≥42 μg/mL)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vaccine and Placebo
Number of subjects: 300
Study: 23025511

Group type: EXPERIMENTAL
Intervention: OC000459 200 mg bid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19142771

Group type: EXPERIMENTAL
Intervention: Pyramids and Palm Trees Test (PPT)
Number of subjects: 0
Study: 17336224

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3DTRUS imaging
Number of subjects: 10

Group type: COMPARATOR
Intervention: CT/MR comparison
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3DTRUS/MR comparison
Number of subjects: 10

Group type: COMPARATOR
Intervention: CT/3DTRUS comparison
Number of subjects: 10
Study: 15449264

Group type: EXPERIMENTAL
Intervention: Complete enteral nutrition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hypocaloric nutrition
Number of subjects: 18
Study: 11403182

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled peptide P483H (29 microg, n = 11; 145 microg, n = 10; 290 microg, n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled peptide P483H
Number of subjects: 30

Group type: COMPARATOR
Intervention: In vitro-labeled leukocyte scintigraphy (n = 20)
Number of subjects: 30
Study: 9489266

Group type: EXPERIMENTAL
Intervention: RCTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative research approaches
Number of subjects: 0
Study: 7803209

Group type: EXPERIMENTAL
Intervention: Octreotide acetate 0.1 mg s.c. 45 minutes before ERCP, followed by another dose 6 hours later.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo s.c.
Number of subjects: 100
Study: 3149400

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 31344519

Group type: EXPERIMENTAL
Intervention: Single level intervention delivered only to the adolescent (AO)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Multi-level intervention delivered to both the adolescent and a parent (A + P)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Both AO and A + P groups
Number of subjects: 114
Study: 28154996

Group type: EXPERIMENTAL
Intervention: Nanostructured calcium‐incorporated (NCI) implants
Number of subjects: 15

Group type: COMPARATOR
Intervention: Machined (MA) implants
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison between NCI and MA implants
Number of subjects: 15
Study: 25257978

Group type: EXPERIMENTAL
Intervention: Bupropion and cognitive behavioral therapy
Number of subjects: 349
Study: 23442255

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (2,400 mg/day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 20688474

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU twice daily)
Number of subjects: 0
Study: 19748402

Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC) treatment for MTrPs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment for MTrPs
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham Ultrasound (Control)
Number of subjects: 66
Study: 16703539

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.02%
Number of subjects: 62
Study: 14984378

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12765427

Group type: EXPERIMENTAL
Intervention: Salbutamol via Clickhaler DPI (0, 100, 200, or 400 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salbutamol via Ventolin pMDI (0, 100, 200, or 400 microg)
Number of subjects: 18
Study: 10945088

Group type: EXPERIMENTAL
Intervention: Antidepressant trials with improved blindness procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled studies
Number of subjects: 0
Study: 9127371

Group type: EXPERIMENTAL
Intervention: 1 gm/day ceftriaxone
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2 million U penicillin G every 4 hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 90
Study: 1550533

Group type: EXPERIMENTAL
Intervention: Buccal scopolamine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3545883

Group type: EXPERIMENTAL
Intervention: Ambroxol 120 mg daily
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ambroxol 60 mg daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 30367613

Group type: EXPERIMENTAL
Intervention: SMS-based mobile intervention (MyTeen) for parents, tailored programme of text messages over 4 weeks
Number of subjects: 214

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: SMS-based mobile intervention (MyTeen)
Number of subjects: 214
Study: 27753434

Group type: EXPERIMENTAL
Intervention: Educational video on clear liquid diet (4-min video provided 48-72 hours before CLS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard pre-procedure instructions (no video)
Number of subjects: 92
Study: 25535596

Group type: EXPERIMENTAL
Intervention: Higher left ventricular ejection fraction (LVEF) associated with female sex and greater BMI
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lower left ventricular ejection fraction (LVEF) associated with pacemaker/defibrillator use and methamphetamine use
Number of subjects: 151
Study: 22240792

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (Bev) 5 mg kg(‐1) every 2 weeks (Arm-A)
Number of subjects: 333

Group type: COMPARATOR
Intervention: CAPIRI plus bevacizumab (Bev) 7.5 mg kg(‐1) every 3 weeks (Arm-B)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: CAPIRI plus bevacizumab (Bev)
Number of subjects: 333
Study: 21349059

Group type: EXPERIMENTAL
Intervention: Revised STRICTA checklist for acupuncture reporting guidelines
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Revised STRICTA checklist
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Collaboration between STRICTA Group, CONSORT Group, and Chinese Cochrane Centre
Number of subjects: 47
Study: 18691392

Group type: EXPERIMENTAL
Intervention: Pedometer plus theory-based intervention (with 20% monthly increase target)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pedometer plus theory-based intervention (with 10% and 15% monthly increase targets)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Theory-based intervention alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pedometer group overall
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 54
Study: 15850917

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.8 mg, orally once a day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 14672523

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited resection (sublobar resection, wedge resection, segmentectomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional open thoracotomy
Number of subjects: 0
Study: 10617258

Group type: EXPERIMENTAL
Intervention: Painful event
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nonpain event
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Baseline event
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Interrater reliability of PIPP scores
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intrarater reliability of PIPP scores
Number of subjects: 43
Study: 8950881

Group type: EXPERIMENTAL
Intervention: MNrgp120 vaccine
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study: 1768822

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 89

Group type: COMPARATOR
Intervention: Inactive TENS (Control)
Number of subjects: 89
Study: 7043385

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 200 mg administered intramuscularly four times at three-week intervals
Number of subjects: 16

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 16
Study: 30714427

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 0.5 ml platelet-rich plasma (PRP) 48 hours before blastocyst transfer
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 97
Study: 31097515

Group type: EXPERIMENTAL
Intervention: CPAP treatment in non-dipper patients
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: CPAP treatment in dipper patients
Number of subjects: 272
Study: 27987395

Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI at 25cmH2O for 15s)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard resuscitation (Non‐SLI group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI)
Number of subjects: 81
Study: 25359163

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (4000 IU/d)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Low-dose vitamin D3 (400 IU/d)
Number of subjects: 534
Study: 23603644

Group type: EXPERIMENTAL
Intervention: Prefabricated wrist splint
Number of subjects: 94

Group type: COMPARATOR
Intervention: Short-arm cast
Number of subjects: 94
Study: 21333020

Group type: EXPERIMENTAL
Intervention: 12-week pedometer-based graduated walking programme and physical activity consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-week waiting list control group (delayed group)
Number of subjects: 0
Study: 19569065

Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (200 mcg)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 193
Study: 16890144

Group type: EXPERIMENTAL
Intervention: High sodium diet (HS) > 200 mmol Na/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low sodium diet (LS) < 10 mmol Na/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High sodium diet (HS) response to Ang II infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low sodium diet (LS) response to Ang II infusion
Number of subjects: 13
Study: 15006280

Group type: COMPARATOR
Intervention: Male faculty - Male resident dyad (reference comparison)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Female faculty - Male resident dyad
Number of subjects: 160

Group type: COMPARATOR
Intervention: Male faculty - Female resident dyad
Number of subjects: 160

Group type: COMPARATOR
Intervention: Female faculty - Female resident dyad
Number of subjects: 160
Study: 11869164

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Systematic reviews
Number of subjects: 2376
Study: 9677796

Group type: EXPERIMENTAL
Intervention: Oral mesoglycan (200 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 2
Study: 7926242

Group type: EXPERIMENTAL
Intervention: Goserelin depot therapy for 2 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (proliferative phase of the cycle)
Number of subjects: 55
Study: 2911851

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Withdrawal of the therapeutic drug monitoring program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinstitution of the therapeutic drug monitoring program
Number of subjects: 0
Study: 1110818

Group type: EXPERIMENTAL
Intervention: Suction curettage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dilatation and curettage
Number of subjects: 60
Study: 6107136

Group type: EXPERIMENTAL
Intervention: Propranolol at a dose level of 1,280‐1,920 mg per day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study: 31748296

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted oesophagectomy (LAO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open oesophagectomy (OO)
Number of subjects: 0
Study: 28958651

Group type: EXPERIMENTAL
Intervention: 0.23% ropivacaine at 5 ml/h
Number of subjects: 99

Group type: COMPARATOR
Intervention: 0.9% saline at 5 ml/h
Number of subjects: 99
Study: 26945812

Group type: EXPERIMENTAL
Intervention: Low-fat milk consumption (200 mL twice daily for 6 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (maintaining habitual diet)
Number of subjects: 58
Study: 24215623

Group type: EXPERIMENTAL
Intervention: Group 1 (GD without TAO)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Group 2 (GD with TAO)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Group 3 (Healthy participants)
Number of subjects: 97
Study: 22385444

Group type: EXPERIMENTAL
Intervention: Patelloplasty (Group A)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Traditional treatment (Group B)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 152